东软集团股份有限公司关于参与认购投资基金份额的公告

Core Viewpoint - The company has invested 30 million yuan in the Jinan Mingxin Industrial Investment Fund, acquiring a 22.54% share of the total subscribed capital, aligning with its strategic focus on the "big health" sector [1][2]. Group 1: Investment Details - The company acts as a limited partner in the fund, contributing 30 million yuan, which represents 22.54% of the total subscribed capital of 133.1 million yuan [2][16]. - The fund has an operational period of 8 years, with a 4-year investment phase [2][21]. - The investment does not require approval from the company's board or shareholders and is not classified as a related party transaction or a major asset restructuring [3][1]. Group 2: Fund Management and Structure - The fund is managed by Shanghai Mingxin Private Equity Fund Management Partnership, which is responsible for investment decisions and daily operations [9]. - The management fee is set at 1.5% per year during the investment period and 2% per year during the recovery period [10]. - Profit distribution follows a specific order, prioritizing the return of capital to limited partners before any profit sharing [11][18]. Group 3: Investment Focus and Strategy - The fund aims to invest in equity of growth-stage companies in the biopharmaceutical and healthcare sectors, seeking capital appreciation [12]. - The exit mechanisms include project exit distributions, partner withdrawals, and share transfers, ensuring flexibility for limited partners [13][14]. Group 4: Impact on the Company - This investment aligns with the company's strategic development and industry chain layout, leveraging professional investment experience and resources for long-term growth [23]. - The investment will not significantly impact the company's daily operations and will not be included in the company's consolidated financial statements [23].